Bullish & Foolish
Full CLRB fundamentals All 466 on the Survival Watch

CLRBCellectar Biosciences, Inc.

Is Cellectar Biosciences struggling financially?

Yes, by its own account. Cellectar Biosciences told the SEC on 28 May 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$24.5M
Source filing
DEF 14A 28 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 14months

    If the burn speeds up

    Empty by Aug 2027

  • 21months

    If it eases off

    Empty by Mar 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$34.0M

÷

Cash burned over the last 12 months

$23.1M

What Cellectar Biosciences told the SEC

…as to uncertainty, audit scope or accounting principles, except that such report contained an explanatory paragraph in respect to uncertainty, raising substantial doubt as to the Company’s ability to continue as a going concern. During the fiscal year ended December 31, 2023, and the subsequent interim period through July 8, 2024, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of…

Cellectar Biosciences, Inc., Form DEF 14A, filed 28 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 425.1% share-count increase The company issued stock. Each share now owns 81.0% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 68% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt